Boehringer Ingelheim

Since its establishment in 1970, the Paulson Investment Company has carved out a strong position as one of the leading investment bankers that specializes in small and emerging growth opportunities with capital needs from $5 million to $40 million. As one of the country s most active SmallCap investment bankers, Paulson works with some of the most successful entrepreneurs. The company is also one of the largest independent brokerage firms and is one of the leading investment bankers for emerging companies nationwide. Paulson offers a range of investment vehicles and insight into emerging business opportunities, online services and responsive support from broker to back office. The Paulson Investment Company maintains offices in Portland, Ore.

Gelesis is a biotechnology company based in Boston, MA, specializing in the development of innovative therapies for gastrointestinal (GI)-related chronic diseases. Their unique approach involves the use of superabsorbent hydrogels that mimic the properties of raw vegetables, which are administered in capsule form to act locally in the stomach and intestines. Their portfolio includes an FDA-cleared product, Plenity, designed to aid in weight management, as well as potential therapies in development for Type 2 Diabetes, Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH), and Functional Constipation. Gelesis' hydrogel technology platform offers a safe and convenient alternative for individuals seeking weight management solutions without resorting to surgery or stimulants. By increasing the volume and firmness of consumed foods while reducing caloric density, their products help empower people to improve their diet, lifestyle, and overall health. With a focus on biomimicry and utilizing naturally-derived building blocks, Gelesis is at the forefront of developing groundbreaking treatments for GI-related chronic diseases.Generated from the website

Apellis Pharmaceuticals, Inc., located in Waltham, MA, is dedicated to advancing innovation in complement science, aiming to transform treatment for patients suffering from a variety of debilitating diseases. With a commitment to embracing community voices, the company has achieved two product approvals in less than two years, underlining its focus on courageous and compassionate science. The company's pipeline reflects its mission to challenge conventional thinking and explore better solutions in healthcare. Apellis Pharmaceuticals is actively seeking experts to join their team as they work towards developing life-changing medicines across multiple rare disease research areas. Generated from the website